Dimensional Fund Advisors LP Has $2.54 Million Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

Dimensional Fund Advisors LP grew its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 44.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,557,496 shares of the company's stock after acquiring an additional 478,596 shares during the quarter. Dimensional Fund Advisors LP owned 0.70% of Sana Biotechnology worth $2,538,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Cerity Partners LLC bought a new stake in shares of Sana Biotechnology in the fourth quarter valued at approximately $25,000. Blue Trust Inc. lifted its position in Sana Biotechnology by 51.0% in the fourth quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock worth $32,000 after purchasing an additional 6,694 shares during the period. Ieq Capital LLC bought a new position in Sana Biotechnology in the fourth quarter worth $32,000. KLP Kapitalforvaltning AS bought a new position in Sana Biotechnology in the fourth quarter worth $39,000. Finally, Teacher Retirement System of Texas lifted its position in Sana Biotechnology by 20.3% in the fourth quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company's stock worth $60,000 after purchasing an additional 6,209 shares during the period. 88.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on SANA. Jefferies Financial Group began coverage on Sana Biotechnology in a research report on Friday, March 14th. They issued a "buy" rating and a $7.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Sana Biotechnology in a report on Thursday, April 24th. Finally, Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a report on Tuesday, March 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Price Performance

Shares of NASDAQ:SANA traded down $0.02 during midday trading on Tuesday, reaching $1.66. The company's stock had a trading volume of 386,786 shares, compared to its average volume of 3,349,348. Sana Biotechnology, Inc. has a fifty-two week low of $1.26 and a fifty-two week high of $9.02. The company has a market capitalization of $374.74 million, a P/E ratio of -1.18 and a beta of 1.75. The business's fifty day simple moving average is $1.83 and its 200-day simple moving average is $2.39.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. On average, analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.